On Nov 06, 2025, ZYME reported earnings of -0.26 USD per share (EPS) for Q3 25, beating the estimate of -0.32 USD, resulting in a 20.63% surprise. Revenue reached 27.61 million, compared to an expected 30.05 million, with a -8.10% difference. The market reacted with a -8.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.43 USD, with revenue projected to reach 13.85 million USD, implying an increase of 65.38% EPS, and decrease of -49.85% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Zymeworks Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Zymeworks Inc. reported EPS of -$0.26, beating estimates by 20.63%, and revenue of $27.61M, -8.1% below expectations.
How did the market react to Zymeworks Inc.'s Q3 2025 earnings?
The stock price moved down -8.04%, changed from $17.90 before the earnings release to $16.46 the day after.
When is Zymeworks Inc. expected to report next?
The next earning report is scheduled for Mar 03, 2026.
What are the forecasts for Zymeworks Inc.'s next earnings report?
Based on 14
analysts, Zymeworks Inc. is expected to report EPS of -$0.43 and revenue of $13.85M for Q4 2025.